Who is eligible for MIPS 410?

All patients with a diagnosis of psoriasis vulgaris and treated with a systemic medication.

Is MIPS 410 the same as MIPS 410?

Yes. CMS uses zero-padded three-digit Quality IDs (410) in official specifications, while clinicians often search for MIPS 410 or Quality ID 410 without the leading zero. Both refer to the same 2026 MIPS quality measure reported through the Quality Payment Program (QPP).

What codes do I submit for MIPS 410: Psoriasis: Clinical Response to Systemic Medications?

Submission codes: G9649 (Psoriasis assessment tool documented meeting any one of the specified benchmarks (e.g., (PGA; 5-point OR 6- point scale), body surface area (BSA), psoriasis area and severity index (PASI) and/or dermatology life quality index (DLQI))); G9651 (Psoriasis assessment tool documented not meeting any one of the specified benchmarks (e.g., (PGA; 5-point OR 6-point scale), body surface area (BSA), psoriasis area and severity index (PASI) and/or dermatology life quality index (DLQI)) or psoriasis assessment tool not documented)

How do I report MIPS Measure 410 in 2026?

MIPS Measure 410 (Quality ID 410) is reported through the Quality Payment Program (QPP) as a MIPS Clinical Quality Measure (CQM) via qualified registry, or Medicare Part B claims where applicable.

Is MIPS 410 a topped-out measure?

No, MIPS 410 is not topped out, meaning there is still meaningful performance variation across clinicians.

Measure ID: MIPS 410|Dermatology|2026 Performance Year

2026 MIPS Measure #410: Psoriasis: Clinical Response to Systemic Medications

Percentage of psoriasis vulgaris patients receiving systemic medication who meet minimal physician-or patient- reported disease activity levels. It is implied that establishment and maintenance of an established minimum level of disease control as measured by physician-and/or patient-reported outcomes will increase patient satisfaction with and adherence to treatment.

Intermediate Outcome – High PriorityDermatologyMedication Management

Measure ID:MIPS 410 (Quality ID 410)

Collection:MIPS CQM

Topped Out:No

View CMS Spec ↗

Measure Specification

Eligible Population

All patients, regardless of age

ANDDiagnosis for psoriasis vulgaris

ANDPatient encounter during the performance period

ANDPatient has been treated with a systemic medication for psoriasis vulgaris

Exclusions

None

Numerator

Patients who have a documented physician global assessment (PGA; 5-point OR 6-point scale), body surface area (BSA), psoriasis area and severity index (PASI) and/or dermatology life quality index (DLQI) that meet any one of the below specified benchmarks.

Reporting Codes

Performance Met:

G9649Psoriasis assessment tool documented meeting any one of the specified benchmarks (e.g., (PGA; 5-point OR 6- point scale), body surface area (BSA), psoriasis area and severity index (PASI) and/or dermatology life quality index (DLQI))

Performance Not Met:

G9651Psoriasis assessment tool documented not meeting any one of the specified benchmarks (e.g., (PGA; 5-point OR 6-point scale), body surface area (BSA), psoriasis area and severity index (PASI) and/or dermatology life quality index (DLQI)) or psoriasis assessment tool not documented

○ Exceptions:

G9765Documentation that the patient declined change in medication or alternative therapies were unavailable, has documented contraindications, or has not been treated with a systemic medication for at least six consecutive months (e.g., experienced adverse effects or lack of efficacy with all other therapy options) in order to achieve better disease control as measured by PGA, BSA, PASI, or DLQI

VBCA Insights

Why This Measure Matters

Psoriasis patients on systemic medications (biologics, methotrexate, etc.) should achieve minimal disease activity—a goal measured by physician global assessment, body surface area percentage, PASI score, or DLQI. Many patients remain dissatisfied despite treatment; this measure rewards achieving real disease control, not just 'some improvement.' Good performance requires patient engagement in monitoring, honest discussions about side effects vs. benefits, and willingness to switch or combine therapies until targets are met.

VBCA is a CMS-approved Qualified Clinical Data Registry (QCDR) that submits MIPS Measure 410 to the Quality Payment Program (QPP). Practices can report this measure as a MIPS Clinical Quality Measure (CQM) or through qualified registry submission.

🧮MIPS Score Simulator

Estimate only — actual CMS scoring may vary based on reporting method, data completeness, and annual rule updates.

Your Performance Rate:%Benchmarks vary by collection type

💡 Tip: Enter your performance rate to compare MIPS points across all collection types. The same rate can score differently depending on how you submit.

Specialty Measure Sets

Dermatology

Related Measures

Dermatology

MIPS 250: Radical Prostatectomy Pathology Reporting MIPS 397: Melanoma Reporting MIPS 440: Skin Cancer: Biopsy Reporting Time – Pathologist to Clinician MIPS 485: Psoriasis – Improvement in Patient-Reported Itch Severity MIPS 486: Dermatitis – Improvement in Patient-Reported Itch Severity MIPS 509: Melanoma: Tracking and Evaluation of Recurrence

Medication Management

MIPS 005: Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or MIPS 007: Coronary Artery Disease (CAD): Beta-Blocker Therapy – Prior Myocardial MIPS 008: Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic MIPS 118: Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE)MIPS 130: Documentation of Current Medications in the Medical Record MIPS 180: Rheumatoid Arthritis (RA): Glucocorticoid Management MIPS 268: Epilepsy: Counseling for Women of Childbearing Potential with Epilepsy MIPS 468: Continuity of Pharmacotherapy for Opioid Use Disorder (OUD)MIPS 489: Adult Kidney Disease: Angiotensin Converting Enzyme (ACE) Inhibitor or MIPS 490: Appropriate Intervention of Immune-Related Diarrhea and/or Colitis in Patients Treated

Official Resources

📄 CMS Measure Specification (PDF)🔗 QPP Quality Payment Program

Clinical Rationale

A significant proportion of psoriasis patients who are receiving treatment remain unsatisfied with their therapies due to various reasons including lack of or loss of efficacy, side effects, and inconvenience, among others. Treatment dissatisfaction also contributes to patients discontinuing their medication. This measure evaluates the proportion of psoriasis vulgaris patients receiving systemic medication who meet minimal physician or patient-reported disease activity levels.

It is implied that establishment and maintenance of an established minimum level of disease control as measured by physician and/or patient-reported outcomes will increase patient satisfaction with and adherence to treatment.

Clinical Recommendations

1. Treatment goals (assessment after 10 to 16 weeks, and every 8 weeks thereafter): PASI 75 or PGA of ‘clear’ or ‘almost clear’; or DLQI of 0 or 1 (Pathirana, 2009). 2. Minimum efficiency (‘lowest hurdle’): PASI 50; DLQI<5 or improvement by at least 5 points (Pathirana, 2009). 3. Continue therapy if PASI 75 response (or if PASI 50 response and DLQI≤5) (Mrowietz, 2011).

4. Adequate response to treatment is defined as either: a. PASI 50 response (or ≥50% improvement in BSA) and ≥5-point improvement in DLQI; or b. PASI 75 response (Smith, 2009). 5. Treatment ‘success’ defined as PASI 75 response (or PASI 50 response and DLQI≤5) (Baker, 2013).

Implementation Notes

This measure contains one strata defined by a single submission criteria. This measure produces a single performance rate. For the purposes of MIPS implementation, this patient-intermediate measure is submitted a minimum of once per patient during the performance period. The most recent quality data code will be used if the measure is submitted more than once.

Report this measure through VBCA

Our QCDR handles measure selection, data validation, and submission—so you can focus on clinical performance.

Learn About Our QCDR →Talk to Us